Most studies investigating the effects of β3AR agonists in HF demonstrated that β3AR agonists attenuated cardiac fibrosis and improved cardiac contractility via the β3AR/eNOS/cGMP signaling pathway as the main mechanism [21,55]. This evidence concerns the gene NOS3 and hydrops fetalis.